Bryan Haugen
Concepts (494)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 88 | 2024 | 277 | 17.040 |
Why?
| Thyroid Nodule | 17 | 2024 | 38 | 4.020 |
Why?
| Carcinoma, Papillary | 24 | 2017 | 78 | 3.900 |
Why?
| Thyroid Gland | 25 | 2018 | 86 | 3.700 |
Why?
| Iodine Radioisotopes | 25 | 2022 | 128 | 3.530 |
Why?
| Endocrinology | 10 | 2020 | 69 | 3.480 |
Why?
| Adenocarcinoma, Follicular | 17 | 2022 | 34 | 2.970 |
Why?
| Thyrotropin | 28 | 2023 | 108 | 2.870 |
Why?
| Carcinoma | 9 | 2015 | 212 | 1.830 |
Why?
| Thyroid Diseases | 8 | 2020 | 32 | 1.660 |
Why?
| Retinoid X Receptors | 11 | 2011 | 38 | 1.440 |
Why?
| Antineoplastic Agents | 15 | 2022 | 1990 | 1.430 |
Why?
| Retinoids | 7 | 2011 | 35 | 1.350 |
Why?
| Thyroidectomy | 15 | 2021 | 54 | 1.320 |
Why?
| Tetrahydronaphthalenes | 6 | 2015 | 32 | 1.310 |
Why?
| Thyroid Carcinoma, Anaplastic | 6 | 2019 | 37 | 1.290 |
Why?
| Hypothyroidism | 7 | 2023 | 69 | 1.270 |
Why?
| Thyroxine | 11 | 2023 | 64 | 1.190 |
Why?
| Biomarkers, Tumor | 14 | 2019 | 1076 | 1.180 |
Why?
| Receptors, Retinoic Acid | 7 | 2004 | 42 | 1.150 |
Why?
| Biopsy, Fine-Needle | 9 | 2021 | 71 | 1.070 |
Why?
| NF-kappa B | 3 | 2015 | 676 | 1.050 |
Why?
| Carcinoma, Papillary, Follicular | 4 | 2014 | 8 | 1.000 |
Why?
| Lymphatic Metastasis | 6 | 2018 | 310 | 0.960 |
Why?
| Neoplasm Proteins | 6 | 2013 | 415 | 0.930 |
Why?
| Transcription Factors | 15 | 2014 | 1616 | 0.920 |
Why?
| Cell Line, Tumor | 19 | 2020 | 2904 | 0.920 |
Why?
| Gene Expression Profiling | 6 | 2020 | 1625 | 0.910 |
Why?
| Ultrasonography | 7 | 2024 | 740 | 0.910 |
Why?
| Struma Ovarii | 2 | 2014 | 7 | 0.860 |
Why?
| Radiopharmaceuticals | 3 | 2012 | 196 | 0.830 |
Why?
| Humans | 127 | 2024 | 122796 | 0.830 |
Why?
| Proto-Oncogene Proteins B-raf | 3 | 2023 | 204 | 0.790 |
Why?
| Neoplasm Invasiveness | 6 | 2017 | 472 | 0.780 |
Why?
| Promoter Regions, Genetic | 14 | 2018 | 1188 | 0.760 |
Why?
| Thiazolidinediones | 4 | 2018 | 155 | 0.750 |
Why?
| Pituitary Gland | 6 | 2011 | 164 | 0.750 |
Why?
| History, 20th Century | 7 | 2018 | 288 | 0.740 |
Why?
| Oncogene Proteins, Fusion | 2 | 2019 | 182 | 0.740 |
Why?
| Lymph Nodes | 5 | 2018 | 466 | 0.710 |
Why?
| Cell Differentiation | 5 | 2020 | 1805 | 0.700 |
Why?
| Neoplasm Metastasis | 10 | 2015 | 563 | 0.670 |
Why?
| T-Lymphocytes, Regulatory | 3 | 2015 | 367 | 0.660 |
Why?
| Triiodothyronine | 4 | 2017 | 45 | 0.660 |
Why?
| History, 21st Century | 6 | 2018 | 177 | 0.640 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 243 | 0.630 |
Why?
| Hypothalamus | 2 | 2011 | 155 | 0.630 |
Why?
| Mutation | 11 | 2023 | 3493 | 0.610 |
Why?
| Programmed Cell Death 1 Receptor | 3 | 2016 | 201 | 0.610 |
Why?
| Societies, Medical | 6 | 2020 | 741 | 0.590 |
Why?
| Ovarian Neoplasms | 2 | 2014 | 460 | 0.590 |
Why?
| Neoplasm Staging | 14 | 2021 | 1234 | 0.580 |
Why?
| Multimodal Imaging | 2 | 2014 | 102 | 0.580 |
Why?
| Molecular Targeted Therapy | 3 | 2015 | 361 | 0.570 |
Why?
| Transcriptome | 3 | 2020 | 774 | 0.560 |
Why?
| Drug Resistance, Neoplasm | 3 | 2016 | 673 | 0.560 |
Why?
| Pharmacogenomic Testing | 1 | 2016 | 54 | 0.560 |
Why?
| Recombinant Proteins | 8 | 2009 | 1318 | 0.550 |
Why?
| Immunotherapy, Adoptive | 1 | 2017 | 192 | 0.540 |
Why?
| DNA-Binding Proteins | 13 | 2014 | 1384 | 0.540 |
Why?
| Terminology as Topic | 1 | 2017 | 217 | 0.540 |
Why?
| Protein-Tyrosine Kinases | 1 | 2019 | 442 | 0.530 |
Why?
| Thyroid Hormones | 4 | 2020 | 56 | 0.520 |
Why?
| Famous Persons | 1 | 2014 | 6 | 0.510 |
Why?
| Databases, Genetic | 1 | 2016 | 257 | 0.510 |
Why?
| Anticarcinogenic Agents | 1 | 2015 | 70 | 0.500 |
Why?
| Gene Expression Regulation, Neoplastic | 7 | 2018 | 1183 | 0.500 |
Why?
| Physician Executives | 1 | 2014 | 37 | 0.500 |
Why?
| Tomography, Emission-Computed, Single-Photon | 2 | 2014 | 108 | 0.490 |
Why?
| Hyperthyroidism | 2 | 2012 | 27 | 0.490 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2014 | 1003 | 0.480 |
Why?
| Genes, Tumor Suppressor | 1 | 2014 | 79 | 0.480 |
Why?
| Neoplasm Transplantation | 5 | 2019 | 248 | 0.480 |
Why?
| Data Collection | 2 | 2016 | 667 | 0.480 |
Why?
| Medical Oncology | 1 | 2016 | 231 | 0.470 |
Why?
| Combined Modality Therapy | 8 | 2021 | 1174 | 0.460 |
Why?
| Gene Expression | 2 | 2012 | 1506 | 0.460 |
Why?
| Interleukin-8 | 1 | 2014 | 256 | 0.450 |
Why?
| Thyroglobulin | 6 | 2013 | 18 | 0.450 |
Why?
| Proteomics | 3 | 2010 | 890 | 0.450 |
Why?
| Research | 1 | 2016 | 432 | 0.430 |
Why?
| Neovascularization, Pathologic | 1 | 2014 | 292 | 0.420 |
Why?
| Mice | 27 | 2022 | 15888 | 0.420 |
Why?
| RNA, Messenger | 15 | 2012 | 2720 | 0.420 |
Why?
| Pituitary Gland, Anterior | 4 | 2002 | 46 | 0.420 |
Why?
| Radiotherapy, Adjuvant | 2 | 2012 | 191 | 0.420 |
Why?
| Middle Aged | 32 | 2021 | 28563 | 0.410 |
Why?
| Cell Proliferation | 9 | 2019 | 2328 | 0.410 |
Why?
| Decision Support Techniques | 1 | 2015 | 392 | 0.410 |
Why?
| Bone Neoplasms | 2 | 2012 | 197 | 0.400 |
Why?
| Female | 48 | 2023 | 63629 | 0.400 |
Why?
| Telomerase | 5 | 2019 | 213 | 0.390 |
Why?
| Practice Guidelines as Topic | 5 | 2020 | 1519 | 0.390 |
Why?
| DNA, Neoplasm | 2 | 2008 | 155 | 0.380 |
Why?
| T-Lymphocytes | 2 | 2017 | 1814 | 0.370 |
Why?
| PPAR gamma | 3 | 2009 | 191 | 0.370 |
Why?
| Blotting, Western | 8 | 2014 | 1225 | 0.370 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2013 | 1402 | 0.360 |
Why?
| Animals | 31 | 2022 | 34133 | 0.360 |
Why?
| Male | 42 | 2023 | 59639 | 0.360 |
Why?
| MAP Kinase Kinase 2 | 1 | 2009 | 27 | 0.360 |
Why?
| Carrier Proteins | 1 | 2014 | 740 | 0.360 |
Why?
| Protein Kinase Inhibitors | 2 | 2013 | 833 | 0.350 |
Why?
| Prognosis | 11 | 2018 | 3563 | 0.350 |
Why?
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 12 | 0.350 |
Why?
| Cell Culture Techniques | 2 | 2009 | 354 | 0.350 |
Why?
| MAP Kinase Kinase 1 | 1 | 2009 | 67 | 0.350 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 27 | 0.350 |
Why?
| Neoplasm Recurrence, Local | 6 | 2024 | 903 | 0.340 |
Why?
| Aged | 21 | 2021 | 20495 | 0.340 |
Why?
| Forkhead Transcription Factors | 1 | 2010 | 188 | 0.340 |
Why?
| Iodide Peroxidase | 2 | 2005 | 25 | 0.330 |
Why?
| Benzodioxoles | 1 | 2009 | 83 | 0.320 |
Why?
| Hormone Replacement Therapy | 2 | 2020 | 80 | 0.320 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2009 | 196 | 0.310 |
Why?
| MAP Kinase Signaling System | 1 | 2009 | 304 | 0.310 |
Why?
| Quinazolines | 1 | 2009 | 243 | 0.300 |
Why?
| Cell Transformation, Neoplastic | 2 | 2012 | 320 | 0.300 |
Why?
| Signal Transduction | 5 | 2016 | 4902 | 0.300 |
Why?
| Adult | 30 | 2021 | 32385 | 0.290 |
Why?
| S100 Proteins | 1 | 2006 | 35 | 0.290 |
Why?
| Disease-Free Survival | 5 | 2021 | 661 | 0.280 |
Why?
| Treatment Outcome | 16 | 2018 | 9692 | 0.280 |
Why?
| Lipoprotein Lipase | 2 | 2004 | 69 | 0.280 |
Why?
| Neoplasms | 3 | 2016 | 2235 | 0.280 |
Why?
| Tomography, X-Ray Computed | 3 | 2018 | 2500 | 0.270 |
Why?
| Molecular Diagnostic Techniques | 2 | 2021 | 94 | 0.270 |
Why?
| Evidence-Based Medicine | 3 | 2020 | 731 | 0.270 |
Why?
| Apoptosis | 4 | 2012 | 2532 | 0.260 |
Why?
| Mice, Nude | 5 | 2018 | 668 | 0.260 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 783 | 0.260 |
Why?
| Melanoma | 2 | 2009 | 709 | 0.260 |
Why?
| Tumor Cells, Cultured | 8 | 2009 | 904 | 0.260 |
Why?
| Goiter, Nodular | 1 | 2004 | 1 | 0.260 |
Why?
| Retinoid X Receptor gamma | 1 | 2004 | 4 | 0.260 |
Why?
| Chromosomal Proteins, Non-Histone | 2 | 2002 | 103 | 0.250 |
Why?
| Galectin 3 | 1 | 2004 | 20 | 0.250 |
Why?
| Sensitivity and Specificity | 6 | 2024 | 1855 | 0.250 |
Why?
| United States | 13 | 2023 | 13272 | 0.250 |
Why?
| Retrospective Studies | 9 | 2023 | 13433 | 0.250 |
Why?
| Dietary Fats | 2 | 2004 | 325 | 0.240 |
Why?
| Microtubule-Associated Proteins | 2 | 2002 | 187 | 0.240 |
Why?
| Immunohistochemistry | 7 | 2020 | 1727 | 0.240 |
Why?
| Diagnosis, Differential | 5 | 2013 | 1423 | 0.240 |
Why?
| Drug Resistance | 2 | 2022 | 169 | 0.230 |
Why?
| Molecular Sequence Data | 13 | 2006 | 2933 | 0.230 |
Why?
| Prospective Studies | 12 | 2023 | 6704 | 0.230 |
Why?
| Tamoxifen | 2 | 2020 | 198 | 0.220 |
Why?
| Cell Cycle Proteins | 1 | 2006 | 576 | 0.220 |
Why?
| Benzoates | 3 | 2009 | 41 | 0.210 |
Why?
| Cytodiagnosis | 1 | 2021 | 29 | 0.200 |
Why?
| Phenylurea Compounds | 1 | 2022 | 84 | 0.200 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2020 | 747 | 0.200 |
Why?
| Lymphoma | 1 | 2002 | 185 | 0.200 |
Why?
| Quinolines | 1 | 2022 | 127 | 0.200 |
Why?
| Thyroid Hormone Resistance Syndrome | 1 | 2000 | 1 | 0.190 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2016 | 715 | 0.190 |
Why?
| Consensus | 3 | 2020 | 554 | 0.190 |
Why?
| Aged, 80 and over | 8 | 2021 | 6845 | 0.190 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2008 | 2127 | 0.190 |
Why?
| Radionuclide Imaging | 3 | 2010 | 134 | 0.190 |
Why?
| Base Sequence | 11 | 2002 | 2186 | 0.180 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2020 | 32 | 0.180 |
Why?
| Adenocarcinoma | 3 | 2017 | 837 | 0.180 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2010 | 135 | 0.180 |
Why?
| Nitriles | 2 | 2010 | 158 | 0.170 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2022 | 537 | 0.170 |
Why?
| Antigens, Neoplasm | 1 | 2020 | 228 | 0.170 |
Why?
| Transfection | 5 | 2005 | 909 | 0.170 |
Why?
| Thyrotropin, beta Subunit | 2 | 2011 | 5 | 0.160 |
Why?
| Receptors, Estrogen | 1 | 2020 | 388 | 0.160 |
Why?
| Workflow | 1 | 2018 | 148 | 0.160 |
Why?
| Neck | 2 | 2015 | 90 | 0.150 |
Why?
| Tissue Extracts | 1 | 2017 | 21 | 0.150 |
Why?
| Disease Progression | 6 | 2020 | 2546 | 0.150 |
Why?
| Up-Regulation | 1 | 2020 | 891 | 0.150 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 177 | 0.150 |
Why?
| Heterografts | 2 | 2015 | 132 | 0.150 |
Why?
| Muscle, Skeletal | 2 | 2004 | 1556 | 0.140 |
Why?
| Transcription Factor Pit-1 | 8 | 1999 | 23 | 0.140 |
Why?
| Parathyroidectomy | 1 | 2016 | 7 | 0.140 |
Why?
| Tretinoin | 1 | 1997 | 119 | 0.140 |
Why?
| Colorado | 3 | 2014 | 4325 | 0.140 |
Why?
| Homeodomain Proteins | 3 | 1999 | 484 | 0.140 |
Why?
| Enzyme Inhibitors | 2 | 2010 | 836 | 0.140 |
Why?
| Ligands | 3 | 2009 | 582 | 0.140 |
Why?
| Diet | 1 | 2023 | 1168 | 0.140 |
Why?
| Caspase 7 | 1 | 2015 | 23 | 0.140 |
Why?
| Prolactin | 2 | 1999 | 97 | 0.140 |
Why?
| Bortezomib | 1 | 2015 | 49 | 0.130 |
Why?
| Larynx | 1 | 2016 | 57 | 0.130 |
Why?
| Inhibitory Concentration 50 | 1 | 2015 | 82 | 0.130 |
Why?
| Hypocalcemia | 1 | 2015 | 32 | 0.130 |
Why?
| User-Computer Interface | 1 | 2016 | 164 | 0.130 |
Why?
| Information Storage and Retrieval | 1 | 2016 | 131 | 0.130 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 115 | 0.130 |
Why?
| Radiation, Ionizing | 1 | 2015 | 74 | 0.130 |
Why?
| Pharmacogenetics | 1 | 2016 | 151 | 0.130 |
Why?
| Double-Blind Method | 2 | 2012 | 1711 | 0.130 |
Why?
| Taxoids | 1 | 2015 | 98 | 0.130 |
Why?
| Laryngoscopy | 1 | 2016 | 99 | 0.130 |
Why?
| Immunophenotyping | 2 | 2015 | 288 | 0.130 |
Why?
| Transcriptional Activation | 2 | 1994 | 360 | 0.130 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2019 | 466 | 0.130 |
Why?
| Immunotherapy | 2 | 2016 | 504 | 0.130 |
Why?
| Energy Metabolism | 1 | 2000 | 783 | 0.130 |
Why?
| Societies, Scientific | 1 | 2014 | 49 | 0.120 |
Why?
| Guidelines as Topic | 1 | 2016 | 273 | 0.120 |
Why?
| Predictive Value of Tests | 2 | 2019 | 1947 | 0.120 |
Why?
| NF-KappaB Inhibitor alpha | 1 | 2014 | 52 | 0.120 |
Why?
| Caspase 3 | 1 | 2015 | 246 | 0.120 |
Why?
| Growth Hormone | 1 | 1994 | 109 | 0.120 |
Why?
| Algorithms | 4 | 2018 | 1593 | 0.120 |
Why?
| DNA Mutational Analysis | 2 | 2020 | 390 | 0.120 |
Why?
| Histiocytoma, Benign Fibrous | 1 | 1994 | 6 | 0.120 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 240 | 0.120 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2013 | 14 | 0.120 |
Why?
| I-kappa B Proteins | 1 | 2014 | 81 | 0.120 |
Why?
| Graves Disease | 2 | 2012 | 33 | 0.120 |
Why?
| ROC Curve | 1 | 2015 | 494 | 0.120 |
Why?
| Cell Death | 1 | 2015 | 345 | 0.120 |
Why?
| Transduction, Genetic | 1 | 2014 | 118 | 0.120 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2014 | 93 | 0.120 |
Why?
| Stilbenes | 1 | 2013 | 36 | 0.120 |
Why?
| Drug Resistance, Multiple | 1 | 2013 | 19 | 0.120 |
Why?
| Transcription, Genetic | 5 | 2011 | 1355 | 0.110 |
Why?
| Sirolimus | 1 | 2014 | 198 | 0.110 |
Why?
| Registries | 6 | 2015 | 2020 | 0.110 |
Why?
| Observer Variation | 1 | 2013 | 314 | 0.110 |
Why?
| Genetic Variation | 1 | 2018 | 952 | 0.110 |
Why?
| Nuclear Proteins | 1 | 1997 | 618 | 0.110 |
Why?
| Disease Models, Animal | 3 | 2019 | 3799 | 0.110 |
Why?
| Contraindications | 1 | 2012 | 102 | 0.110 |
Why?
| T-Lymphocyte Subsets | 2 | 2015 | 409 | 0.100 |
Why?
| Protein Isoforms | 2 | 2004 | 347 | 0.100 |
Why?
| Receptors, Thyroid Hormone | 3 | 1996 | 20 | 0.100 |
Why?
| Thiazoles | 1 | 2012 | 125 | 0.100 |
Why?
| src-Family Kinases | 1 | 2012 | 109 | 0.100 |
Why?
| Young Adult | 5 | 2019 | 11094 | 0.100 |
Why?
| Thyroiditis, Autoimmune | 2 | 2020 | 17 | 0.100 |
Why?
| Glycoprotein Hormones, alpha Subunit | 1 | 2011 | 22 | 0.100 |
Why?
| Genomics | 1 | 2016 | 714 | 0.100 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2014 | 377 | 0.100 |
Why?
| Mice, 129 Strain | 1 | 2011 | 80 | 0.100 |
Why?
| Quality Improvement | 1 | 2018 | 1004 | 0.100 |
Why?
| Risk Assessment | 3 | 2015 | 3213 | 0.100 |
Why?
| Pilot Projects | 1 | 2015 | 1477 | 0.100 |
Why?
| Oleanolic Acid | 1 | 2010 | 9 | 0.090 |
Why?
| Polymerase Chain Reaction | 4 | 2005 | 1021 | 0.090 |
Why?
| Whole Body Imaging | 1 | 2010 | 25 | 0.090 |
Why?
| Weight Gain | 2 | 2023 | 511 | 0.090 |
Why?
| Endometrial Neoplasms | 2 | 2002 | 144 | 0.090 |
Why?
| Ribonucleases | 3 | 2002 | 54 | 0.090 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 2 | 2008 | 108 | 0.090 |
Why?
| Dopamine Agonists | 1 | 2009 | 30 | 0.090 |
Why?
| Cells, Cultured | 3 | 2014 | 4162 | 0.090 |
Why?
| Diphosphonates | 1 | 2010 | 51 | 0.090 |
Why?
| Lymphocyte Subsets | 1 | 2010 | 78 | 0.090 |
Why?
| Somatostatin | 1 | 2009 | 54 | 0.090 |
Why?
| Amino Acid Sequence | 4 | 2006 | 2123 | 0.090 |
Why?
| Antibody Specificity | 1 | 2010 | 190 | 0.090 |
Why?
| Lymphoma, T-Cell | 1 | 2009 | 22 | 0.090 |
Why?
| Breast Neoplasms | 2 | 2020 | 1994 | 0.090 |
Why?
| Sulfones | 1 | 2010 | 102 | 0.090 |
Why?
| Butadienes | 1 | 2009 | 34 | 0.090 |
Why?
| Bone Density Conservation Agents | 1 | 2010 | 61 | 0.090 |
Why?
| Postoperative Complications | 2 | 2023 | 2301 | 0.090 |
Why?
| Calcium | 1 | 2015 | 1244 | 0.090 |
Why?
| Hysterectomy | 1 | 2010 | 119 | 0.090 |
Why?
| Pyrimidines | 1 | 2012 | 388 | 0.090 |
Why?
| Radiotherapy | 1 | 2010 | 187 | 0.080 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2009 | 190 | 0.080 |
Why?
| Benzamides | 1 | 2009 | 175 | 0.080 |
Why?
| Adolescent | 6 | 2023 | 18948 | 0.080 |
Why?
| Membrane Proteins | 1 | 2015 | 1093 | 0.080 |
Why?
| Drug Evaluation, Preclinical | 1 | 2009 | 187 | 0.080 |
Why?
| Time Factors | 3 | 2010 | 6682 | 0.080 |
Why?
| Flow Cytometry | 1 | 2012 | 1128 | 0.080 |
Why?
| Phosphorylation | 2 | 2012 | 1733 | 0.080 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2015 | 1003 | 0.080 |
Why?
| Cell Line | 3 | 2019 | 2785 | 0.080 |
Why?
| Adenoma | 2 | 2002 | 196 | 0.080 |
Why?
| Lymphocyte Activation | 1 | 2012 | 1148 | 0.080 |
Why?
| Cohort Studies | 5 | 2023 | 5294 | 0.080 |
Why?
| Proportional Hazards Models | 3 | 2023 | 1184 | 0.070 |
Why?
| Phenotype | 3 | 2015 | 3070 | 0.070 |
Why?
| Enzyme Activation | 1 | 2009 | 864 | 0.070 |
Why?
| S100 Calcium Binding Protein A6 | 1 | 2006 | 1 | 0.070 |
Why?
| Reproducibility of Results | 2 | 2019 | 2977 | 0.070 |
Why?
| RNA, Small Interfering | 1 | 2009 | 581 | 0.070 |
Why?
| Pituitary Neoplasms | 2 | 1999 | 166 | 0.070 |
Why?
| Colonic Neoplasms | 1 | 2008 | 230 | 0.070 |
Why?
| Brain Neoplasms | 1 | 2014 | 1016 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2009 | 312 | 0.070 |
Why?
| Metformin | 1 | 2009 | 303 | 0.070 |
Why?
| Fatty Acids, Nonesterified | 1 | 2006 | 173 | 0.070 |
Why?
| Postoperative Care | 2 | 2018 | 245 | 0.070 |
Why?
| Neoplasm Grading | 2 | 2018 | 265 | 0.070 |
Why?
| Autoantibodies | 1 | 2013 | 1353 | 0.070 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 114 | 0.070 |
Why?
| Inhibitor of Apoptosis Proteins | 2 | 2002 | 44 | 0.070 |
Why?
| Chromatin Immunoprecipitation | 1 | 2005 | 139 | 0.070 |
Why?
| RNA, Neoplasm | 2 | 2002 | 79 | 0.070 |
Why?
| Glucocorticoids | 1 | 2009 | 554 | 0.070 |
Why?
| Blotting, Southern | 2 | 1996 | 68 | 0.070 |
Why?
| Preoperative Care | 2 | 2018 | 342 | 0.060 |
Why?
| Paclitaxel | 1 | 2006 | 202 | 0.060 |
Why?
| Chromosome Mapping | 2 | 1997 | 518 | 0.060 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2004 | 12 | 0.060 |
Why?
| Quality of Life | 3 | 2022 | 2457 | 0.060 |
Why?
| Tomography, Emission-Computed | 1 | 2004 | 59 | 0.060 |
Why?
| DNA, Mitochondrial | 1 | 2005 | 189 | 0.060 |
Why?
| Organic Chemicals | 1 | 2005 | 132 | 0.060 |
Why?
| Luciferases | 1 | 2004 | 150 | 0.060 |
Why?
| Triglycerides | 1 | 2006 | 527 | 0.060 |
Why?
| Immunoprecipitation | 1 | 2004 | 170 | 0.060 |
Why?
| Cell Cycle Checkpoints | 2 | 2016 | 89 | 0.060 |
Why?
| Heart Neoplasms | 2 | 2015 | 51 | 0.060 |
Why?
| Probability | 2 | 2021 | 316 | 0.060 |
Why?
| Professional Practice | 1 | 2003 | 68 | 0.060 |
Why?
| Protein Binding | 1 | 2009 | 2010 | 0.060 |
Why?
| Computers | 1 | 2023 | 66 | 0.060 |
Why?
| National Institutes of Health (U.S.) | 1 | 2023 | 122 | 0.060 |
Why?
| Genetic Testing | 2 | 2018 | 400 | 0.060 |
Why?
| Magnetic Resonance Imaging | 2 | 2010 | 3264 | 0.050 |
Why?
| Poly A | 1 | 2002 | 48 | 0.050 |
Why?
| 5' Untranslated Regions | 1 | 2002 | 53 | 0.050 |
Why?
| Gene Library | 1 | 2002 | 128 | 0.050 |
Why?
| DNA, Complementary | 1 | 2002 | 270 | 0.050 |
Why?
| Child | 1 | 2021 | 19561 | 0.050 |
Why?
| Point Mutation | 1 | 2002 | 231 | 0.050 |
Why?
| Cell Division | 1 | 2004 | 788 | 0.050 |
Why?
| Endometrium | 1 | 2002 | 61 | 0.050 |
Why?
| Thallium Radioisotopes | 1 | 2001 | 7 | 0.050 |
Why?
| Thallium | 1 | 2001 | 3 | 0.050 |
Why?
| Carcinoma, Endometrioid | 1 | 2002 | 47 | 0.050 |
Why?
| Organotechnetium Compounds | 1 | 2001 | 17 | 0.050 |
Why?
| Biopsy, Needle | 1 | 2002 | 192 | 0.050 |
Why?
| Macrophages | 2 | 2020 | 1334 | 0.050 |
Why?
| Plasmids | 1 | 2002 | 358 | 0.050 |
Why?
| Survival Analysis | 3 | 2010 | 1325 | 0.050 |
Why?
| Life Style | 1 | 2023 | 436 | 0.050 |
Why?
| Thyroid Function Tests | 2 | 2017 | 11 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 1 | 2005 | 1981 | 0.050 |
Why?
| Cell Cycle | 1 | 2004 | 584 | 0.050 |
Why?
| MutS Homolog 2 Protein | 1 | 2020 | 14 | 0.050 |
Why?
| MCF-7 Cells | 1 | 2020 | 115 | 0.050 |
Why?
| Health Status | 1 | 2006 | 758 | 0.050 |
Why?
| Calcitonin | 1 | 2020 | 28 | 0.050 |
Why?
| Mice, Transgenic | 1 | 2005 | 2079 | 0.050 |
Why?
| Receptors, Virus | 1 | 2020 | 78 | 0.050 |
Why?
| Pituitary Hormones | 1 | 1999 | 17 | 0.050 |
Why?
| Models, Animal | 1 | 2022 | 373 | 0.050 |
Why?
| Mice, SCID | 1 | 2020 | 339 | 0.050 |
Why?
| Risk Factors | 3 | 2023 | 9381 | 0.040 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2020 | 143 | 0.040 |
Why?
| Singapore | 1 | 2019 | 15 | 0.040 |
Why?
| Validation Studies as Topic | 1 | 2019 | 21 | 0.040 |
Why?
| Octreotide | 1 | 1999 | 27 | 0.040 |
Why?
| Lymphoma, T-Cell, Cutaneous | 1 | 1999 | 42 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2022 | 573 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2022 | 988 | 0.040 |
Why?
| Leukocytes | 1 | 2020 | 295 | 0.040 |
Why?
| Immune System | 1 | 2020 | 184 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2020 | 588 | 0.040 |
Why?
| Surveys and Questionnaires | 3 | 2020 | 4882 | 0.040 |
Why?
| Adenoma, Oxyphilic | 1 | 2018 | 4 | 0.040 |
Why?
| Luminescence | 1 | 2018 | 35 | 0.040 |
Why?
| DNA Mismatch Repair | 1 | 2018 | 29 | 0.040 |
Why?
| Delphi Technique | 1 | 2018 | 170 | 0.040 |
Why?
| Pharmacogenomic Variants | 1 | 2018 | 35 | 0.040 |
Why?
| Follow-Up Studies | 4 | 2009 | 4768 | 0.040 |
Why?
| Radiation Tolerance | 1 | 1999 | 98 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 884 | 0.040 |
Why?
| North America | 1 | 2018 | 271 | 0.040 |
Why?
| Age Factors | 3 | 2015 | 3114 | 0.040 |
Why?
| Oncogenes | 1 | 2018 | 118 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2018 | 195 | 0.040 |
Why?
| Dietary Carbohydrates | 1 | 1998 | 154 | 0.040 |
Why?
| Doxorubicin | 1 | 1999 | 304 | 0.040 |
Why?
| Liver | 1 | 2005 | 1827 | 0.040 |
Why?
| Soft Tissue Neoplasms | 1 | 2018 | 95 | 0.040 |
Why?
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 70 | 0.040 |
Why?
| Gene Frequency | 1 | 2018 | 522 | 0.040 |
Why?
| Advisory Committees | 1 | 2018 | 229 | 0.040 |
Why?
| Health Policy | 1 | 2020 | 356 | 0.040 |
Why?
| Stroboscopy | 1 | 2016 | 6 | 0.040 |
Why?
| Tissue Distribution | 1 | 1997 | 339 | 0.040 |
Why?
| DNA | 4 | 1996 | 1401 | 0.040 |
Why?
| DNA Fingerprinting | 1 | 1996 | 26 | 0.030 |
Why?
| Deoxyribonuclease I | 1 | 1996 | 36 | 0.030 |
Why?
| RNA | 1 | 2002 | 854 | 0.030 |
Why?
| Immunomodulation | 1 | 2016 | 91 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 459 | 0.030 |
Why?
| Surgeons | 1 | 2020 | 245 | 0.030 |
Why?
| Tumor Suppressor Proteins | 1 | 2018 | 299 | 0.030 |
Why?
| Antithyroid Agents | 2 | 2006 | 11 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2020 | 985 | 0.030 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 1995 | 31 | 0.030 |
Why?
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2015 | 30 | 0.030 |
Why?
| Lymphocyte Count | 1 | 2015 | 141 | 0.030 |
Why?
| Mutagenesis, Site-Directed | 1 | 1996 | 368 | 0.030 |
Why?
| Mutagenesis, Insertional | 1 | 1994 | 62 | 0.030 |
Why?
| Cytotoxicity, Immunologic | 1 | 2015 | 204 | 0.030 |
Why?
| Microsatellite Repeats | 1 | 2014 | 147 | 0.030 |
Why?
| Adipose Tissue | 1 | 1998 | 616 | 0.030 |
Why?
| Mice, Knockout | 1 | 2020 | 2737 | 0.030 |
Why?
| Age of Onset | 1 | 2015 | 479 | 0.030 |
Why?
| Computational Biology | 1 | 2018 | 601 | 0.030 |
Why?
| Killer Cells, Natural | 1 | 2016 | 386 | 0.030 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1995 | 232 | 0.030 |
Why?
| Gene Expression Regulation | 4 | 1997 | 2491 | 0.030 |
Why?
| Head and Neck Neoplasms | 1 | 2018 | 475 | 0.030 |
Why?
| Genes, Neoplasm | 1 | 2013 | 22 | 0.030 |
Why?
| Risk | 2 | 2006 | 890 | 0.030 |
Why?
| Preoperative Period | 1 | 2013 | 112 | 0.030 |
Why?
| Alternative Splicing | 1 | 1994 | 197 | 0.030 |
Why?
| Gene Deletion | 1 | 1994 | 365 | 0.030 |
Why?
| Neutropenia | 1 | 2013 | 134 | 0.030 |
Why?
| Case-Control Studies | 2 | 2015 | 3296 | 0.030 |
Why?
| DNA, Single-Stranded | 1 | 1993 | 114 | 0.030 |
Why?
| Postoperative Period | 1 | 2013 | 317 | 0.030 |
Why?
| Focal Adhesion Kinase 1 | 1 | 2012 | 29 | 0.030 |
Why?
| Reference Values | 2 | 2005 | 789 | 0.030 |
Why?
| Dasatinib | 1 | 2012 | 48 | 0.030 |
Why?
| Recurrence | 1 | 2015 | 998 | 0.030 |
Why?
| Genetic Markers | 1 | 2013 | 358 | 0.030 |
Why?
| Repressor Proteins | 1 | 1995 | 384 | 0.030 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 1995 | 354 | 0.020 |
Why?
| Tumor Burden | 1 | 2012 | 277 | 0.020 |
Why?
| Age Distribution | 1 | 2012 | 376 | 0.020 |
Why?
| Sex Distribution | 1 | 2012 | 370 | 0.020 |
Why?
| Longevity | 1 | 2012 | 156 | 0.020 |
Why?
| Universities | 1 | 2013 | 356 | 0.020 |
Why?
| Autophagy | 1 | 2014 | 321 | 0.020 |
Why?
| Interleukin-6 | 1 | 2014 | 702 | 0.020 |
Why?
| Obesity | 1 | 2023 | 2786 | 0.020 |
Why?
| Protein Processing, Post-Translational | 1 | 2012 | 421 | 0.020 |
Why?
| Menopause | 1 | 2012 | 270 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2020 | 4734 | 0.020 |
Why?
| Early Detection of Cancer | 1 | 2013 | 364 | 0.020 |
Why?
| Cell Survival | 1 | 2012 | 1075 | 0.020 |
Why?
| Exons | 2 | 2002 | 310 | 0.020 |
Why?
| Insulin | 1 | 1998 | 2180 | 0.020 |
Why?
| Calreticulin | 1 | 2008 | 25 | 0.020 |
Why?
| Binding Sites | 3 | 1996 | 1247 | 0.020 |
Why?
| Physical Examination | 1 | 2009 | 253 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2009 | 757 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 1928 | 0.020 |
Why?
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2006 | 7 | 0.020 |
Why?
| Whole-Body Counting | 1 | 2006 | 5 | 0.020 |
Why?
| Chromans | 1 | 2006 | 21 | 0.020 |
Why?
| Feasibility Studies | 1 | 2009 | 780 | 0.020 |
Why?
| Radiotherapy Dosage | 1 | 2006 | 244 | 0.020 |
Why?
| International Cooperation | 1 | 2006 | 182 | 0.020 |
Why?
| Angiogenesis Inhibitors | 1 | 2006 | 223 | 0.020 |
Why?
| Inflammation | 1 | 2014 | 2598 | 0.010 |
Why?
| Radiography | 1 | 2006 | 888 | 0.010 |
Why?
| Neoplasm, Residual | 1 | 2003 | 104 | 0.010 |
Why?
| Peptides | 1 | 2008 | 893 | 0.010 |
Why?
| Culture Techniques | 1 | 2002 | 81 | 0.010 |
Why?
| Biopsy | 1 | 2006 | 1090 | 0.010 |
Why?
| Models, Biological | 1 | 2008 | 1756 | 0.010 |
Why?
| Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| Steroidogenic Factor 1 | 1 | 1999 | 6 | 0.010 |
Why?
| Gonadotropins | 1 | 1999 | 38 | 0.010 |
Why?
| Pain | 1 | 2006 | 746 | 0.010 |
Why?
| Postmenopause | 1 | 2002 | 307 | 0.010 |
Why?
| Carcinoma, Medullary | 1 | 1998 | 14 | 0.010 |
Why?
| Follicle Stimulating Hormone | 1 | 1999 | 218 | 0.010 |
Why?
| Analysis of Variance | 1 | 2002 | 1329 | 0.010 |
Why?
| DNA Primers | 1 | 1999 | 540 | 0.010 |
Why?
| GATA2 Transcription Factor | 1 | 1997 | 11 | 0.010 |
Why?
| Organ Specificity | 1 | 1998 | 287 | 0.010 |
Why?
| Logistic Models | 1 | 2002 | 1995 | 0.010 |
Why?
| Sequence Deletion | 1 | 1996 | 175 | 0.010 |
Why?
| 3T3 Cells | 1 | 1995 | 141 | 0.010 |
Why?
| Muridae | 1 | 1995 | 4 | 0.010 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 104 | 0.010 |
Why?
| Replication Protein C | 1 | 1995 | 4 | 0.010 |
Why?
| Hybrid Cells | 1 | 1995 | 46 | 0.010 |
Why?
| Macromolecular Substances | 1 | 1995 | 207 | 0.010 |
Why?
| Mutagenesis | 1 | 1995 | 185 | 0.010 |
Why?
| Minor Histocompatibility Antigens | 1 | 1995 | 42 | 0.010 |
Why?
| Mice, Inbred DBA | 1 | 1994 | 185 | 0.010 |
Why?
| Survival Rate | 1 | 1998 | 1810 | 0.010 |
Why?
| Body Weight | 1 | 1998 | 958 | 0.010 |
Why?
| Blotting, Northern | 1 | 1993 | 199 | 0.010 |
Why?
| Cloning, Molecular | 1 | 1994 | 551 | 0.010 |
Why?
| Haplotypes | 1 | 1995 | 482 | 0.010 |
Why?
| Sex Factors | 1 | 1998 | 1860 | 0.010 |
Why?
| Protein Biosynthesis | 1 | 1993 | 408 | 0.010 |
Why?
| Rats | 1 | 1996 | 5426 | 0.000 |
Why?
| Mice, Inbred C57BL | 1 | 1995 | 5020 | 0.000 |
Why?
|
|
Haugen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|